Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat

March 27, 2024

https://www.globenewswire.com/news-release/2024/03/27/2853583/0/en/Sagimet-Biosciences-Announces-Completion-of-Phase-1-Hepatic-Impairment-Study-with-FASN-Inhibitor-Denifanstat.html

SAN MATEO, Calif., March 27, 2024 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Sagimet, Nasdaq:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the completion of a Phase 1 hepatic impairment study with denifanstat, a selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.